Pedro Madureira has graduated in Biochemistry at the Faculty of Sciences of the University of Porto (FCUP) and obtained his PhD in Biomedical Sciences at the Instituto de Ciências Biomédicas Abel Salazar (ICBAS) of the same university.
Pedro Madureira is co-founder and CSO of Immunethep, a biotech company focused on the development of immunotherapies for infectious diseases.
Currently, the main research interest is to understand microbial virulence mechanisms that are responsible to avert host immune system and induce disease. This research led to the development of Immunethep immunotherapies that target an immunosuppressive protein excreted by different bacteria.